66 related articles for article (PubMed ID: 9546519)
1. ATLAS shows global undertreatment of heart failure.
Husten L
Lancet; 1998 Apr; 351(9108):1035. PubMed ID: 9546519
[No Abstract] [Full Text] [Related]
2. Clinical trials update.
Kayser SR
Prog Cardiovasc Nurs; 1997; 12(2):30-3, 44. PubMed ID: 9195645
[No Abstract] [Full Text] [Related]
3. The heart of the matter.
Williams WL
CMAJ; 1997 Dec; 157(12):1673-4. PubMed ID: 9418655
[No Abstract] [Full Text] [Related]
4. ATLAS: high dose lisinopril is superior to low dose in heart failure.
Jackson G
Int J Clin Pract; 1998; 52(3):139. PubMed ID: 9684425
[No Abstract] [Full Text] [Related]
5. Assessment of Treatment with Lisinopril and Survival ATLAS study.
Int J Clin Pract Suppl; 1999 Apr; 100():24. PubMed ID: 10658297
[No Abstract] [Full Text] [Related]
6. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
Goldschmidt-Clermont PJ
J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
[No Abstract] [Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
Lincoff AM; Topol EJ
Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
[No Abstract] [Full Text] [Related]
8. The ATLAS study: low-dose versus high-dose lisinopril in heart failure.
Horowitz JD
Int J Clin Pract Suppl; 1999 Apr; 100():15-6. PubMed ID: 10658293
[No Abstract] [Full Text] [Related]
9. Results of the ATLAS study.
Rydén L
Int J Clin Pract Suppl; 1999 Apr; 100():17-8. PubMed ID: 10658294
[No Abstract] [Full Text] [Related]
10. Implications of the ATLAS study for clinical practice.
Packer M
Int J Clin Pract Suppl; 1999 Apr; 100():21-3. PubMed ID: 10658296
[No Abstract] [Full Text] [Related]
11. Heart failure management in primary care: implications of the ATLAS study.
Int J Clin Pract Suppl; 1999 Apr; 100():25-30. PubMed ID: 10658298
[No Abstract] [Full Text] [Related]
12. Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents.
Gershlick AH
Semin Interv Cardiol; 1998; 3(3-4):185-90. PubMed ID: 10406691
[No Abstract] [Full Text] [Related]
13. Care of the patient receiving ReoPro following angioplasty.
Brezina K; Murphy M; Stonner T
J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
[No Abstract] [Full Text] [Related]
14. Abciximab to prevent vessel closure after angioplasty.
Med Lett Drugs Ther; 1995 Jun; 37(950):52-3. PubMed ID: 7760769
[No Abstract] [Full Text] [Related]
15. The TARGET trial: hit or miss?
Moliterno DJ; Topol EJ
Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001
[No Abstract] [Full Text] [Related]
16. Post-procedural patient management: prevention and management of bleeding complications.
Aguirre F
J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
[No Abstract] [Full Text] [Related]
17. Regimen lowers rate of coronary events in diabetes.
Husten L
Lancet; 1998 Aug; 352(9129):711. PubMed ID: 9728999
[No Abstract] [Full Text] [Related]
18. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
Talley JD
J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
[No Abstract] [Full Text] [Related]
19. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
Topaz O
Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
Rydén L; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Packer M; Poole-Wilson PA
Eur Heart J; 2000 Dec; 21(23):1967-78. PubMed ID: 11071803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
